Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSL889 in Sickle Cell Disease During Vaso-Occlusive Crisis
NCT06699849Phase 2Recruiting
- Sponsor
- CSL Limited
- Start
- Jul 2025
- Primary completion
- Oct 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of hemopexin in vaso-occlusive crisis (VOC) (3 arms), sponsored by CSL Limited. Primary endpoints: Treatment-Emergent Adverse Events, Treatment Emergent anti-CSL889 antibodies and 1 more. Started Jul 2025; status: recruiting.
02
Drugs
hemopexin
03
Conditions
vaso-occlusive crisis (VOC)
Beyond the preview
Go deeper on NCT06699849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06699849.